Novo Nordisk Details Progress of 2026 Share Buyback Programme
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk ( (NVO) ) just unveiled an announcement.
On 4 February 2026, Novo Nordisk A/S launched a share repurchase programme under EU Safe Harbour rules as part of a broader plan to buy back up to DKK 15 billion of shares over a 12‑month period. Under the sub‑programme running from 4 February to 4 May 2026, the company plans to repurchase up to DKK 3.8 billion of its B shares, strengthening capital return to shareholders and potentially supporting its share price.
Between 23 and 27 February 2026, Novo Nordisk bought an additional 1,295,000 B shares, bringing total repurchases under the 2026 programme to 4,045,000 B shares at a transaction value of about DKK 1.16 billion. As of 27 February 2026, Novo Nordisk held 21,434,799 B shares as treasury stock, equal to 0.5% of its share capital, underscoring continued use of buybacks as a key element of its capital allocation strategy.
The most recent analyst rating on (NVO) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases, particularly diabetes. It pioneers scientific breakthroughs, expands access to its medicines and preventive care, employs about 68,800 people in 80 countries, and markets its products in roughly 170 countries, with B shares listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange.
Average Trading Volume: 23,356,074
Technical Sentiment Signal: Sell
Current Market Cap: $166.9B
See more data about NVO stock on TipRanks’ Stock Analysis page.
